You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Mobile App Targeting Meth Use, HIV Sex Risks and ART Adherence for Gay/Bisexual Men
SBC: COG ANALYTICS, LLC Topic: NIDADESCRIPTION (provided by applicant): Methamphetamine use among gay and bisexually identified men (GBM) and other men who have sex with men (MSM) is strongly associated with HIV infection due to the concomitant high-risk sexual behaviors that often occur while using the drug. As a result, HIV prevalence is significantly higher among MSM that report frequent use of methamphetamine and highest among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Mobile Peer Support for Opioid Use Disorders: Refinement of an Innovative Machine Learning Tool
SBC: BEACON TECH INC Topic: R41PROJECT SUMMARY This proposal develops a novelartificial intelligenceAIenabledmobile treatment delivery method that fulfills the need for a robustsecuretechnology based peer support platform to support patients with opioid use disordersOUDsThe majority of individuals with OUDs in the United States do not receive any formal substance use treatmentand growing evidence suggests that many OUD patients ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the Innate Immune System by Fisetin for the Treatment of AD
SBC: VIROGENICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatm ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDFiloviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Multielectrode Arrays for Neurotransmitter Detection with Fast Scan Cyclic Voltammetry
SBC: MICROPROBES FOR LIFE SCIENCE INC Topic: 101Project Summary Abstract The brain is by far the most complex and heterogeneous organ in the human bodyFor yearsthere has been a growing and unmet need to develop multielectrode arrays for neurotransmitter sensing in multiple brain regions simultaneouslyDisparate brain regions such as the nucleus accumbensstriatumprefrontal cortexhippocampusand others have been widely known to have greatly varying ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Multi-Functional Nanotube-Based Sensor Array for Detecting Blood Coagulation Defects
SBC: Innosense Llc Topic: DHA19A001Defense Health Agency (DHA) is seeking a multi-functional diagnostic to determine blood coagulopathy in real time at point-of-care (POC). Blood coagulopathy, resulting in uncontrolled bleeding, is implicated in 80% of operating room deaths and 50% of trau
STTR Phase I 2019 Department of DefenseDefense Health Agency -
Multipurpose reversible terminators
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: NHGRIDESCRIPTION (provided by applicant): This Phase 2 STTR application will allow the Foundation for Applied Molecular Evolution (FfAME) to complete its transfer of technology to Firebird Biomolecular Sciences LLC, allowing Firebird to commercialize nucleoside triphosphates where the 3'-OH groups are blocked by a 3'-ONH2 group. Triphosphates having this modification are accepted by DNA polymerases and ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
MyFAP: A Multimedia Intervention for Adolescents and Young Adults with FAP
SBC: Radiant Creative Group, LLC Topic: NCIDESCRIPTION (provided by applicant): In this Phase II STTR application, we will build upon work conducted in our successful Phase I project which established the technical merit, acceptability and feasibility of developing a Web-based intervention, MyFAP.org, for adolescents and young adults (AYAs) with familial adenomatous polyposis (FAP). The main research goal of Phase II is to evaluate the eff ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Neuroprotective therapy of stroke with HUCNC and simvastatin
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health